Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...

Deutsche Bank lowered the firm’s price target on Galapagos (GLPG) to EUR 22 from EUR 28 and keeps a Hold rating on the shares.Discover the Best ...

Galapagos NV ( AMS:GLPG ) shareholders should be happy to see the share price up 13% in the last week. But will ...

CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian ...

Fintel reports that on February 14, 2025, Morgan Stanley downgraded their outlook for Galapagos NV - Depositary Receipt () ...

In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

In its annual results statement, Galapagos chief financial officer Thad Huston said the firm is moving ahead with a planned split into two publicly-traded companies. The spin-off entity, expected to ...